Search

Anavex Life Sciences Corp

Cerrado

SectorSanidad

3.23 4.19

Resumen

Variación precio

24h

Actual

Mínimo

3.21

Máximo

3.2800000000000002

Métricas clave

By Trading Economics

Ingresos

4.1M

-5.7M

BPA

-0.16

Empleados

34

EBITDA

-821K

-6.5M

Dividendos

By Acuity

Próximas Ganancias

25 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

66M

298M

Apertura anterior

-0.96

Cierre anterior

3.23

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

171 / 340 Clasificación en Healthcare

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ago 2026, 20:06 UTC

Anavex Life Sciences Corp is gaining amid broader market strength, reflecting a robust performance in biotechnology and positive investor sentiment despite no specific company news.

20 ago 2026, 20:01 UTC

Anavex Life Sciences Corp shares are lower today, driven by significant weakness in the Biotechnology sub-sector and broader trends affecting the sector.

19 ago 2026, 19:44 UTC

Anavex Life Sciences Corp is trading sharply higher, reaching a session high and maintaining a position above its 20-day moving average. No specific news was identified.

17 ago 2026, 19:46 UTC

News

Anavex Life Sciences has communicated with stockholders about director nominees amid a "Hold" rating from analysts. Shares are trading roughly flat since Friday's close.

14 ago 2026, 20:13 UTC

Anavex Life Sciences shares are lower in after-market hours, influenced by disappointing U.S. retail sales data and declining consumer sentiment.

13 ago 2026, 22:51 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, continuing a trend of declines over three consecutive sessions. No specific news was identified.

12 ago 2026, 19:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Tuesday's close, despite remaining above the 20-day moving average.

11 ago 2026, 23:22 UTC

Anavex Life Sciences Corp is trading lower in after-market hours with no specific news. The stock remains well above its 20-day moving average.

10 ago 2026, 19:46 UTC

Anavex Life Sciences is trading higher today, despite no specific news. Broader market sentiment is influenced by upcoming inflation data and Fed policy expectations.

7 ago 2026, 22:16 UTC

Anavex Life Sciences Corp is higher in after-market trading, continuing a trend of gains over the last seven sessions, despite no specific news identified.

6 ago 2026, 23:51 UTC

Anavex Life Sciences Corp is rising in after-market trading, reaching a high shortly after the market closed, despite no specific news driving the increase.

5 ago 2026, 21:01 UTC

Anavex Life Sciences shares fell in after-market trading, declining significantly despite being above its 20-day moving average and near the top of its one-month range.

4 ago 2026, 19:51 UTC

Anavex Life Sciences Corp is rising amid broader market strength and a decline in crude oil prices, despite pulling back from earlier session highs.

3 ago 2026, 20:02 UTC

News

Anavex Life Sciences Corp announces board changes amid a proxy fight, urging stockholders to reject PVG Asset Management's attempt to replace the board. Shares are higher.

30 jul 2026, 19:39 UTC

Event

Anavex Life Sciences reported Q2 earnings of -$0.06 per share, beating expectations. Shares remain higher since Wednesday's close despite pulling back from session highs.

29 jul 2026, 22:31 UTC

Anavex Life Sciences Corp shares are higher in after-market trading, reflecting broader market gains following the Federal Reserve's decision to maintain interest rates.

28 jul 2026, 21:01 UTC

Anavex Life Sciences Corp shares are lower in after-market hours, currently 1.45% below their 20-day moving average. No specific news was identified.

27 jul 2026, 20:07 UTC

Anavex Life Sciences Corp shares are higher during Monday's session, maintaining gains since Friday amid broader market trends and easing geopolitical tensions.

24 jul 2026, 17:46 UTC

Anavex Life Sciences Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the move.

21 jul 2026, 19:51 UTC

Anavex Life Sciences is rising during Tuesday's session, recovering from a pre-market low. Broader market sentiment is supported by positive earnings from General Motors and Novartis.

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

171 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat